Joseph Patti
Director/Board Member bij ARMATA PHARMACEUTICALS, INC.
Vermogen: - $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Robin Kramer | F | 58 | 4 jaar | |
Jules Haimovitz | M | 73 | 3 jaar | |
Sarah Schlesinger | M | 64 | 4 jaar | |
David J. McQuillan | M | - |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | - |
Richard Rychlik | M | 68 | 1 jaar | |
Odysseas Kostas | M | 49 | 4 jaar | |
Todd Peterson | M | 66 | 5 jaar | |
Deborah Birx | M | 68 | 1 jaar | |
John H. Untereker | M | 73 |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | - |
Jed Rogers | M | - |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | - |
Larry Lawson | M | - |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | - |
Magnus Hook | M | - |
ECM Biosurgery, Inc.
ECM Biosurgery, Inc. Packaged SoftwareTechnology Services ECM Biosurgery, Inc. develops a proprietary technology platform for bio surgery products. The private company is based in Houston, TX. The CEO of the company is David J. McQuillan. | - |
Mina Pastagia | M | - | 4 jaar | |
Bryan Kadotani | M | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Russell H. Plumb | M | 65 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 12 jaar |
Peter J. Azzarello | M | 53 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 12 jaar |
Jeremy Curnock-Cook | M | 75 | 25 jaar | |
Federica Pericle | M | - |
Agilvax, Inc.
Agilvax, Inc. BiotechnologyHealth Technology Agilvax, Inc. discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. It optimizes lead immunotherapy candidates through an extensive in vitro and in vivo testing process to ensure clinical efficacy. The company was founded in 2011 and is headquartered in Albuquerque, NM. | 6 jaar |
James Fox | M | 73 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 jaar |
Anna Novotney-Barry | F | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 2 jaar |
Brian Varnum | M | 64 | 4 jaar | |
Steven Martin | M | 63 | 3 jaar | |
Erin Butler | F | - | 6 jaar | |
Horacio Ferreira Rueda | M | 54 |
Texas A&M University
| 5 jaar |
Billy Macaulay | M | - |
Texas A&M University
| 5 jaar |
Dusty Culbertson | M | - |
Texas A&M University
| 5 jaar |
Mark Teshoian | M | - |
Texas A&M University
| 5 jaar |
Uday Patel | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 2 jaar |
Julianne Averill | F | 39 | - | |
Ryan Siurek | M | 52 |
Texas A&M University
| 5 jaar |
Brad Elliott Heidelberg | M | 48 |
Texas A&M University
| 4 jaar |
Michael Dunne | M | 64 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
Mindy B. Hegi | F | - |
Texas A&M University
| 5 jaar |
Rudi Reinecke | M | - |
Texas A&M University
| 6 jaar |
Justin N. Trail | M | 52 |
Texas A&M University
| 6 jaar |
Courtney Grobe | F | - |
Texas A&M University
| 5 jaar |
John H. Vernachio | M | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 14 jaar |
Lee Rash | M | - |
Texas A&M University
| 5 jaar |
James E. Howell | M | - |
Texas A&M University
| 8 jaar |
Christopher Abundis | M | 46 |
Texas A&M University
| 5 jaar |
Bryan Lemmerman | M | 49 |
Texas A&M University
| 5 jaar |
Gary J. Brauchle | M | 50 |
Texas A&M University
| 5 jaar |
Arcandra Tahar | M | 53 |
Texas A&M University
| 7 jaar |
Michael Dougherty | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 5 jaar |
Bob wilkinson | M | - |
Texas A&M University
| 5 jaar |
Amy M. Morris | F | - |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | - |
Christopher McGuigan | M | 65 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 5 jaar |
Marc L. Preminger | M | 74 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 9 jaar |
A. Keith Willard | M | 83 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 7 jaar |
Matthew P. Kerin | M | 43 |
Texas A&M University
| 5 jaar |
Armando Anido | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 jaar |
H. Parker | F | 68 | 1 jaar | |
Anne VanLent | F | 76 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
Gabriele Cerrone | M | 52 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 5 jaar |
Russell Medford | M | 69 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 15 jaar |
Mike A. Henos | M | 75 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 15 jaar |
Michael Perry | M | 64 | 1 jaar | |
Todd R. Patrick | M | 61 | 3 jaar | |
John P. Richard | M | 66 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
Richard J. Bastiani | M | 81 | 2 jaar | |
Michael Barrett | M | 81 |
Inhibitex LLC
Inhibitex LLC Pharmaceuticals: MajorHealth Technology Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA. | 10 jaar |
Richard James Hill | M | 77 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 2 jaar |
Brian Szymczak | M | 51 |
Texas A&M University
| 4 jaar |
Tonya McDermott | F | 54 |
Texas A&M University
| 2 jaar |
Kirk M. Stanley | M | - |
Texas A&M University
| 4 jaar |
Zachary Covar | M | - |
Texas A&M University
| 4 jaar |
Dan Varner | M | - |
Texas A&M University
| 4 jaar |
Jill Mason | F | - |
Texas A&M University
| 4 jaar |
Nick Pope | M | - |
Texas A&M University
| 4 jaar |
Todd Hamlin | M | 53 |
Texas A&M University
| 4 jaar |
Chantell Preston | F | - |
Texas A&M University
| 4 jaar |
Sidharta Utama | M | 58 |
Texas A&M University
| 3 jaar |
Katsuhiko Shimizu | M | 60 |
Texas A&M University
| 3 jaar |
Sarah Duggleby | F | - |
Texas A&M University
| 4 jaar |
Eric Hazard | M | - |
Texas A&M University
| 4 jaar |
Jaime Hinojosa | M | - |
Texas A&M University
| 5 jaar |
Meredith Hight | F | - |
Texas A&M University
| 4 jaar |
Adrienne Mangual | F | - |
Texas A&M University
| 4 jaar |
Tommy Woolley | M | - |
Texas A&M University
| 4 jaar |
Jay Wagner | M | - |
Texas A&M University
| 4 jaar |
Curtis A. Hite | M | - |
Texas A&M University
| 1 jaar |
David Fuller | M | - |
Texas A&M University
| 4 jaar |
Jordan Waldrep | M | - |
Texas A&M University
| 4 jaar |
Peng How Wong | M | - |
Texas A&M University
| 4 jaar |
Rae Lynn Schneider | F | - |
Texas A&M University
| 4 jaar |
Blake Cmajdalka | M | - |
Texas A&M University
| 4 jaar |
Ernest Cunningham | M | 54 |
Texas A&M University
| 4 jaar |
James Goerig | M | - |
Texas A&M University
| 4 jaar |
Stephan L. Beatty | M | 57 |
Texas A&M University
| 4 jaar |
Christopher Thomas Wurtz | M | - |
Texas A&M University
| 4 jaar |
Kendra Kinnison | F | - |
Texas A&M University
| 2 jaar |
Stephanie Murphy | F | - |
Texas A&M University
| 4 jaar |
John D. Corbett | M | - |
Texas A&M University
| - |
Dan Victor | M | - |
Texas A&M University
| 4 jaar |
Cassie Meuth | F | - |
Texas A&M University
| 4 jaar |
Bilge Kagan Ceylan | M | 55 |
Texas A&M University
| 1 jaar |
Edward Lewis | M | - |
Texas A&M University
| 4 jaar |
Brent Pilgrim | M | - |
Texas A&M University
| 4 jaar |
William David Dunn | M | - |
Texas A&M University
| 4 jaar |
Karel Svoboda | M | - |
Texas A&M University
| 1 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 100 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Joseph Patti
- Persoonlijk netwerk